Richard Christian Suteja

Mr. Richard Christian Suteja

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MCMatei-Alexandru Cozma
Matei-Alexandru Cozma
Mihnea-Alexandru GamanMihnea-Alexandru Gaman
Mihnea-Alexandru Gaman
BSBahadar S Srichawla
Bahadar S Srichawla
ADArkadeep Dhali
Arkadeep Dhali
MMMuhammad Romail Manan
Muhammad Romail Manan
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Acute cholangitis is a potentially life-threatening bacterial infection of the intra and/or extrahepatic bile ducts. It remains the second and third cause of community-acquired and hospital-acquired bacteremia, respectively, and is associated with mortality rates of up to 15%, despite advances in broad-spectrum antimicrobial therapy and improved access to emergency biliary tract decompression procedures. Even though not much has changed in recent years in terms of diagnosis or treatment, new data have emerged regarding multidrug-resistant bacteria that serve as etiologic agents of cholangitis. Moreover, different approaches in antibiotic regimes depending on severity grading and bile sample cultures as well as novel minimally invasive endoscopic procedures that can help when consecrated treatments such as endoscopic retrograde cholangiopancreatography (ERCP) fail, cannot be performed, or are unavailable have been proposed. This state-of-the-art review aims to offer a complete and updated assessment of the epidemiology, novel diagnostic and therapeutic methods, complications, and prognostic variables of acute cholangitis. The authors will review the prognostic implications of unusual complications, the relevance of regular bile samples and antibiograms, and their new role in guiding antibiotic therapy and limiting antibiotic resistance to present an organized and comprehensive approach to the care of acute cholangitis.

17 May 2024 in Cytokine
Verified
Journal Article
Closed access
Pouya GoleijPouya Goleij
Pouya Goleij
MRMohammad Rahimi
Mohammad Rahimi
MPMotahareh Pourshahroudi
Motahareh Pourshahroudi
MTMohammad Amin Khazeei Tabari
Mohammad Amin Khazeei Tabari
SMSyed Muhammad
Syed Muhammad
PSParniyan Sadeghi
Parniyan Sadeghi

1 January 2025 in Clinics in Orthopedic Surgery
Verified
Journal Article
Open access
PDF file
RSRichard Christian Suteja
Richard Christian Suteja
JHJonathan Edmund Harianto
Jonathan Edmund Harianto
GHGresya Hendrawan
Gresya Hendrawan
VAVioreli Angelina
Vioreli Angelina
IPI Gusti Ngurah Paramartha Wijaya Putra
I Gusti Ngurah Paramartha Wijaya Putra
Suteja RC, et al. Clin Orthop Surg. 2025 Oct;17(5):797-814. https://doi.org/10.4055/cios25023

27 April 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
BSBahadar S Srichawla
Bahadar S Srichawla
Vincent KipkorirVincent Kipkorir
Vincent Kipkorir
MMMuhammad Romail Manan
Muhammad Romail Manan
ADArkadeep Dhali
Arkadeep Dhali
SDSebastian Diebel
Sebastian Diebel
Mihnea-Alexandru GamanMihnea-Alexandru Gaman
Mihnea-Alexandru Gaman
Neurotropic viruses are a threat to human populations due to ongoing zoonosis. A wide array of neurological manifestations can occur most often including parkinsonism, encephalitis/encephalopathy, flaccid myelitis, and Guillain-Barré syndrome. Neuroinvasion occurs through: transneural transmission, blood brain barrier (BBB) dysfunction, and ‘trojan horse’ mechanism or infected immune cell trafficking into the central nervous system (CNS). Transneural transmission occurs through virus mediated hijacking of intracellular transport proteins allowing retrograde viral transport. BBB dysfunction occurs through cytokine storm increasing membrane permissibility. Increased chemokine expression allows leukocyte trafficking to the BBB. Virally infected leukocytes may successfully pass through the BBB allowing the pathogen to infect microglia and other CNS cell types. We define cerebrospinal fluid (CSF) nondetection as a virus’ ability to evade direct CSF detection but still causing significant neurological symptoms and disease. Mechanisms of CSF nondetection include: transneuronal propagation through trans-synaptic transmission, and synaptic microfusion, as well as intrathecal antibody synthesis and virus neutralization. Direct virus detection in CSF is associated with an increased neurological disease burden. However, the lack of CSF detection does not exclude CNS involvement due to possible neuroevasive mechanisms.

28 September 2022 in International Journal of Medical Students
Verified
Journal Article
Open access
PDF file
ANAhmed Nahian
Ahmed Nahian
RSRichard Christian Suteja
Richard Christian Suteja
Duha ShellahDuha Shellah
Duha Shellah
CECiara Egan
Ciara Egan
Mihnea-Alexandru GamanMihnea-Alexandru Gaman
Mihnea-Alexandru Gaman
FBFrancisco J. Bonilla-Escobar
Francisco J. Bonilla-Escobar

14 November 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
ISI Wayan Sumardika
I Wayan Sumardika
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
ADAgus Eka Darwinata
Agus Eka Darwinata
GPGiovanca Verentzia Purnama
Giovanca Verentzia Purnama
JJJerry Jerry
Jerry Jerry
IWI Gede Purna Weisnawa
I Gede Purna Weisnawa
An unknown pneumonia-like disease has emerged in Wuhan, China, in late 2019. It is later named as SARS-CoV-2 which cause COVID-19. This virus spreads easily due to high mobilization and its transmission through droplets or aerosol and fomite. The World Health Organization (WHO) then declared this disease as a global outbreak in March 2020. As the world faces the outbreak of SARS-CoV-2, many researchers race to find the most efficacious treatment for COVID-19. Until now, the most common treatments for COVID-19 were only symptomatic such as decongestant, corticosteroid, interleukin inhibitor, and existing antiviral. The researchers then develop a brand new antiviral that works efficiently to inhibit SARS-CoV-2 and might become prophylaxis. This disease is called Molnupiravir or EIDD-2801, a nucleotide analog which inhibits SARS-CoV-2 replication, resulting in damaged mRNA and lethal virions. Molnupiravir works to produce mutagenesis in RNA viruses and prevent the virus from spreading widely throughout the human body. However, this drug is still needed to undergo clinical trial phase three. In this article, we will discuss how Molnupiravir works and its efficacy compared to existing drugs. This review article aims to provide an update about novel efficacious antiviral for COVID-19, Molnupiravir.